The FDA has approved exactly two Hedgehog pathway inhibitors for basal cell carcinoma — vismodegib and sonidegib — and the clinical question raised in a recent Dermatology Times feature is deceptively simple: when both drugs target the same Smoothened receptor, what actually separates them in practice?

Both agents exist for patients whom surgery and radiation cannot serve: locally advanced BCC where resection would be disfiguring or impractical, and metastatic disease, the rare end of a tumor spectrum driven almost uniformly by constitutive Hedgehog signaling. That shared mechanism is why differentiating the two drugs falls to practical variables rather than to differences in target.

What does the drug class share?

Blockade of Smoothened shuts downstream GLI transcription, and with it the transcriptional program that keeps basal cell carcinoma growing. The clinical consequences of that mechanism overlap heavily between the two molecules:

• Muscle spasms, the most frequently reported class effect and a leading driver of discontinuation
• Dysgeusia and appetite loss, which compound over months of therapy
• Alopecia, fatigue and GI complaints at varying frequencies
• Class teratogenicity, which mandates pregnancy prevention for both drugs

Because adverse events cluster around the mechanism rather than the molecule, tolerance often decides how long a patient stays on therapy — and Hedgehog inhibitors are, in general, long-horizon treatments.

How do the two agents differ?

The Dermatology Times discussion frames the distinction around the decisions clinicians actually make. Four practical axes dominate:

• Dosing schedule, which shapes adherence in a therapy course that can run for many months
• Adverse-event profile, where differences in frequency and severity of spasms, dysgeusia and fatigue can tip the risk–benefit balance for an individual patient
• Longitudinal experience, since one agent has accumulated more years and more treated patients in routine practice
• Patient-specific factors — comorbidities, comedications and the patient's own tolerance history

The feature's core message is that neither drug is generically "better." A patient who develops limiting dysgeusia on one inhibitor may tolerate the other, and clinicians who know where the profiles diverge have a real second-line option rather than a dead end.

Why this matters now

Advanced BCC sits at the intersection of two dermatologic trends: an aging population with decades of cumulative UV exposure, and a shrinking pool of patients for whom surgery is a clean solution. Immunotherapy has entered the conversation for some patients, but Hedgehog inhibition remains the mechanistically matched answer for a tumor whose genetics were worked out earlier than almost any other skin cancer.

That precision carries an obligation. If clinicians treat the two approved inhibitors as interchangeable, they lose the ability to salvage a course when the first drug fails on tolerability rather than on efficacy. Differentiating them — by schedule, by side-effect weighting, by what the published experience supports for a given patient — is what keeps a one-pathway class flexible at the bedside.

The Dermatology Times piece signals where that conversation goes next: with both agents established, the differentiators worth watching are durability of response in real-world cohorts and management strategies that keep patients on therapy longer.